A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Helene Duhamel was recently diagnosed with non-small cell squamous cell lung cancer. Duhamel shares her thoughts on her ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

"Most patients treated for small cell lung cancer experience rapid progression of disease and there is a high unmet need in the advanced setting," he added. "These interim results from the first ...

The first patient has been treated in the pivotal Ideate-Lung02 trial of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage small cell lung cancer (SCLC), comparing ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung cancer (SCLC).